hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-05. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Cost == Prices can vary depending on location, but the average cost of cricket flour is around $40 per pound ($88/kg) (4,200 to 4,800 crickets). This price is inflated due to limited commercialization and few processors.
When spraying microdroplets of water into a mixture of gases assumed to make up the earth's atmosphere before the origin of life, microelectric discharges between oppositely charged microdroplets occurred and was able to produce organic molecules. Silicate. After comparing Miller–Urey experiments conducted in borosilicate glassware with those conducted in Teflon apparatuses, a 2021 paper suggests that the glass reaction vessel acts as a mineral catalyst, implicating silicate rocks as important surfaces in prebiotic Miller–Urey reactions.
When total translated protein was run on an SDS-polyacrylamide gel electrophoresis and sucrose gradient, peaks corresponding to insulin and proinsulin were isolated. However, to the surprise of Weber a third peak was isolated corresponding to a molecule larger than proinsulin. After reproducing the experiment several times, he consistently noted this large peak prior to proinsulin that he determined must be a larger precursor molecule upstream of proinsulin. In May 1975, at the American Diabetes Association meeting in New York, Weber gave an oral presentation of his work where he was the first to name this precursor molecule "preproinsulin". Following this oral presentation, Weber was invited to dinner to discuss his paper and findings by Donald Steiner, a researcher who contributed to the characterization of proinsulin. A year later in April 1976, this molecule was further characterized and sequenced by Steiner, referencing the work and discovery of Hans Weber. Preproinsulin became an important molecule to study the process of transcription and translation. The first genetically engineered (recombinant), synthetic human insulin was produced using E. coli in 1978 by Arthur Riggs and Keiichi Itakura at the Beckman Research Institute of the City of Hope in collaboration with Herbert Boyer at Genentech. Genentech, founded by Swanson, Boyer and Eli Lilly and Company, went on in 1982 to sell the first commercially available biosynthetic human insulin under the brand name Humulin.
Libiguin A is a naturally occurring limonoid found in Neobeguea mahafalensis, a flowering plant found in Madagascar with a long history of traditional medical use. It is a derivative of phragmalin. The compound has been reported to produce highly potent, strong, and long-lasting pro-sexual effects in rodents. The semisynthesis of libiguin A from phragmalin has been described. An analogue also found in Neobeguea mahafalensis, libiguin B, has similar pro-sexual effects but is far less potent in comparison. Another analogue, a synthetic compound known as volufralin (LIB-01; DIC-2024), is under development for the treatment of erectile dysfunction and premature ejaculation. Libiguin A was first described in the scientific literature by 2014.
Sources: en.wikipedia.org
A Latter-day Saint historian in Idaho talked about how previously it was controversial to donate to refugee programs in Idaho (which was attributed to a Fox News story), but a month after Kearon spoke on the subject there were five new refugee charities in Rexburg. On 1 August 2020, Kearon became the senior president of the Seventy. Prior to his appointment to the Quorum of the Twelve, Kearon spoke three times in general conference. In the first, in October 2010, he spoke of being healed spiritually through the atonement of Jesus Christ. He related a story of how he was stung by a scorpion as a child after he disregarded his parents' instruction to wear shoes in the Arabian desert and elected to wear flip flops instead. In April 2016, he spoke of church members' efforts to help refugees. In April 2022, he spoke to those who have survived abuse, violence, or oppression. On 7 December 2023, he was called and ordained an apostle, then set apart as a member of the Quorum of the Twelve Apostles, filling a vacancy created by the death of M. Russell Ballard the prior month.
== Chemical and physical properties == Glucose forms white or colorless solids that are highly soluble in water and acetic acid but poorly soluble in methanol and ethanol. They melt at 146 °C (295 °F) (α) and 150 °C (302 °F) (beta), decompose starting at 188 °C (370 °F) with release of various volatile products, ultimately leaving a residue of carbon. With six carbon atoms, it is classed as a hexose, a subcategory of the monosaccharides. d-Glucose is one of the sixteen aldohexose stereoisomers. The d-isomer, d-glucose, also known as dextrose, occurs widely in nature, but the l-isomer, l-glucose, does not. Glucose can be obtained by hydrolysis of carbohydrates such as milk sugar (lactose), cane sugar (sucrose), maltose, cellulose, glycogen, etc. Dextrose is commonly commercially manufactured from starches, such as corn starch in the US and Japan, from potato and wheat starch in Europe, and from tapioca starch in tropical areas. The manufacturing process uses hydrolysis via pressurized steaming at controlled pH in a jet followed by further enzymatic depolymerization. Unbonded glucose is one of the main ingredients of honey. The term "dextrose" is often used in a clinical (related to patient's health status) or nutritional context (related to dietary intake, such as food labels or dietary guidelines), while "glucose" is used in a biological or physiological context (chemical processes and molecular interactions), but both terms refer to the same molecule, specifically D-glucose.
=== Cystatin C === Problems with creatinine (varying muscle mass, recent meat ingestion (much less dependent on the diet than urea), etc.) have led to evaluation of alternative agents for estimation of GFR. One of these is cystatin C, a ubiquitous protein secreted by most cells in the body (it is an inhibitor of cysteine protease). Cystatin C is freely filtered at the glomerulus. After filtration, Cystatin C is reabsorbed and catabolized by the tubular epithelial cells, with only small amounts excreted in the urine. Cystatin C levels are therefore measured not in the urine, but in the bloodstream. Equations have been developed linking estimated GFR to serum cystatin C levels. Most recently, some proposed equations have combined sex, age, adjusted cystatin C and creatinine. In 2022, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN)'s Joint Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases recommended national efforts to facilitate increased, routine, and timely use of cystatin C. They noted that cystatin C would be useful particularly to confirm estimated GFR in adults who are at risk for or have chronic kidney disease. They suggested that combining filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone.
Sources: en.wikipedia.org
These ultrafine particles are small enough to bypass respiratory defenses and be inhaled deep into the lungs, where they can enter the bloodstream and are associated with severe systemic inflammation, cardiovascular disease, and premature death. Many e-cigarette companies market their products as a smoking cessation aid without evidence of effectiveness. E-cigarette marketing has been found to make unsubstantiated health statements (e.g., that they help one quit smoking) including statements about improving psychiatric symptoms, which may be particularly appealing to smokers with mental illness. E-cigarette marketing advocate weight control and emphasize use of nicotine with many flavors. These marketing angles could particularly entice overweight people, young people, and vulnerable groups. Some e-cigarette companies state that their products are green without supporting evidence which may be purely to increase their sales.
In legal contexts, in situ is often used for its literal sense, meaning 'in its original place'. In Hong Kong, in-situ land exchange refers to a mechanism whereby landowners can swap their existing or expired land leases for new grants covering the same land parcel. This approach facilitates redevelopment—such as modernizing buildings or increasing land usage density—in a crowded, land-scarce environment without displacing ownership from the original location. The Hong Kong government, through the Development Bureau and Lands Department, has implemented arrangements to expedite lease modifications and land exchanges. In public international law, the term in situ is used to distinguish between a government that exercises effective control over a state's territory and population and a government-in-exile, which operates from outside its national borders. A government in situ is the de facto governing authority, while a government-in-exile may still claim legitimacy despite lacking territorial control. The recognition of a government generally depends on its ability to maintain authority over its state, though exceptions exist, particularly when a government-in-exile is displaced due to unlawful foreign occupation.
=== Environmental === Technology can have both positive and negative effects on the environment. Environmental technology describes an array of technologies that seek to reverse, mitigate, or halt environmental damage to the environment. This can include measures to halt pollution through environmental regulations, capture and storage of pollution, or using pollutant byproducts in other industries. Other examples of environmental technology include deforestation and the reversing of deforestation. Emerging technologies in the fields of climate engineering may be able to halt or reverse global warming and its environmental impacts, although this remains highly controversial. As technology has advanced, so too has the negative environmental impact, with increased release of greenhouse gases, including methane, nitrous oxide and carbon dioxide, into the atmosphere, causing the greenhouse effect. This continues to gradually heat the Earth, causing global warming and climate change. Measures of technological innovation correlate with a rise in greenhouse gas emissions.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.